Echocardiographic follow-up of Chlamydia psittaci myocarditis. 2000

A F Schinkel, and J J Bax, and E E van der Wall, and G J Jonkers
University Hospital Leiden, The Netherlands.

Chlamydia psittaci myocarditis has been infrequently reported. A case of serologically confirmed C psittaci myocarditis with dilated left ventricle and severely impaired left ventricular function is described. Serial echocardiograms demonstrated complete recovery after therapy. An early diagnosis has important prognostic implications.

UI MeSH Term Description Entries
D008297 Male Males
D009205 Myocarditis Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies. Carditis,Myocarditides
D009956 Psittacosis Infection with CHLAMYDOPHILA PSITTACI (formerly Chlamydia psittaci), transmitted to humans by inhalation of dust-borne contaminated nasal secretions or excreta of infected BIRDS. This infection results in a febrile illness characterized by PNEUMONITIS and systemic manifestations. Ornithosis,Ornithoses,Psittacoses
D002691 Chlamydophila psittaci A genus of CHLAMYDOPHILA infecting primarily birds. It contains eight known serovars, some of which infect more than one type of host, including humans. Chlamydia psittaci
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D004232 Diuretics Agents that promote the excretion of urine through their effects on kidney function. Diuretic,Diuretic Effect,Diuretic Effects,Effect, Diuretic,Effects, Diuretic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme

Related Publications

A F Schinkel, and J J Bax, and E E van der Wall, and G J Jonkers
April 2024, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases,
A F Schinkel, and J J Bax, and E E van der Wall, and G J Jonkers
January 1996, Cardiology,
A F Schinkel, and J J Bax, and E E van der Wall, and G J Jonkers
January 2023, Infection and drug resistance,
A F Schinkel, and J J Bax, and E E van der Wall, and G J Jonkers
December 1984, Japanese circulation journal,
A F Schinkel, and J J Bax, and E E van der Wall, and G J Jonkers
November 1978, Ugeskrift for laeger,
A F Schinkel, and J J Bax, and E E van der Wall, and G J Jonkers
March 1981, Medicina clinica,
A F Schinkel, and J J Bax, and E E van der Wall, and G J Jonkers
April 1988, Lancet (London, England),
A F Schinkel, and J J Bax, and E E van der Wall, and G J Jonkers
August 2001, Medizinische Monatsschrift fur Pharmazeuten,
A F Schinkel, and J J Bax, and E E van der Wall, and G J Jonkers
January 1994, Ryoikibetsu shokogun shirizu,
A F Schinkel, and J J Bax, and E E van der Wall, and G J Jonkers
July 1980, Infection and immunity,
Copied contents to your clipboard!